Concepedia

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Kamal S. Saini, Carlo Lanza, Marco Romano, Evandro de Azambuja, Javier Cortés, Begoña de las Heras, Monika Lamba Saini, Sibylle Loibl, Giuseppe Curigliano, Chris Twelves,

British Journal of Cancer · 2020 · 46 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

References

8

COVID-19: consider cytokine storm syndromes and immunosuppression

Puja Mehta, Daniel F. McAuley, Michael Brown et al. · The Lancet · 2020 · 10.2K citations · Full text

, , +16

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Frederikus A. Klok, Marieke J.H.A. Kruip, Nardo J. M. van der Meer et al. · Thrombosis Research · 2020 · 5.2K citations · Full text

, , +13

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020

Shikha Garg, Lindsay Kim, Michael Whitaker et al. · MMWR Morbidity and Mortality Weekly Report · 2020 · 2.5K citations · Full text

, , +16

Cytokine release syndrome in severe COVID-19

John B. Moore, Carl H. June · Science · 2020 · 2K citations

, , +17

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Ishan Paranjpe, Valentı́n Fuster, Anuradha Lala et al. · Journal of the American College of Cardiology · 2020 · 984 citations · Full text

, , +10